Update on Hypertension

A CPhA Webinar

October 20, 2014 • 6:30 pm – 7:30 pm PST

Speaker:  Nathan Painter, Pharm.D., CDE, 
Associate Clinical Professor, UCSD Skaggs School of Pharmacy

Hypertension remains one of the most important preventable contributors to disease and death. Abundant evidence from randomized controlled trials (RCTs) has shown benefit of antihypertensive drug treatment in reducing important health outcomes in persons with hypertension. Clinical guidelines are at the intersection between research evidence and clinical actions that can improve patient outcomes.  With many delays and much speculation, the updated hypertension guidelines (JNC8) were released earlier this year.


Learning Objectives:
  1. Identify 3 differences in the new HTN guidelines (JNC 8) and previous guidelines
  2. Establish goals of therapy based on risk factors according to the guidelines
  3. List first and second line agents used in the treatment of HTN


AUDIENCE: 
This program is targeted to pharmacists.

 Registration Fees** Registration Fee
Received by October 15, 2014
CPhA Member   $49
Non-Member            
 $99

**Registration fees are non-refundable and non-transferrable under any circumstances.**

CONTINUING PHARMACY EDUCATION
The California Pharmacists Association (#0113) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Upon completing an evaluation form, participants will be awarded 1 hour (0.1 CEUs) of Continuing Pharmacy Education Credit.  A statement of credit will not be issued.  Participants may log onto the CPE monitor website using their individual log in to download their statement of credit.  Please allow 4 weeks for processing of CPE credits to the CPE monitor.  UAN: 0113-0000-14-582-L04-P